Table 1 Participant demographics and clinical characteristics (n = 59)
Mean (SD) or n (%) | Range | ||
|---|---|---|---|
Age | 49 (11.2) | 29–75 | |
BMI | 29 (5.7) | 18–42 | |
Menopausal Status | |||
Pre-menopausal | 36 (61%) | ||
Post-menopausal | 23 (39%) | ||
Treatment | |||
Adjuvant | 32 (54%) | ||
Neoadjuvant | 27 (46%) | ||
Chemotherapy | |||
Taxane-based | 34 (58%) | ||
Anthracycline- and taxane-based | 25 (42%) | ||
Tumor Receptor Status | |||
ER+ | 39 (66%) | ||
PR+ | 29 (49%) | ||
HER2+ | 21 (36%) | ||
